IOTA-5: International Ovarian Tumour Analysis (IOTA) Phase 5

Sponsor
KU Leuven (Other)
Overall Status
Unknown status
CT.gov ID
NCT01698632
Collaborator
(none)
15,000
1
119
126.1

Study Details

Study Description

Brief Summary

The purpose of this study is to learn more about the appearance and behavior of benign-looking adnexal masses.

  • Benign-looking means that when viewed here by ultrasound it has the appearance of looking not harmful or not malignant.

  • Adnexal refers to the 'adnexa', the space in the female pelvis on either side of the uterus (or where the uterus used to be if you previously had a hysterectomy). The adnexa includes, but is not limited to, the ovaries and the fallopian tubes.

  • Masses refers to a variety of structures, including but not limited to:

  • ovarian cysts that are fluid filled sacs within or attached to an ovary

  • ovarian tumors that can be solid tissue or a combination of cysts and solid tissue

  • hydrosalpinges that are fluid collections in the fallopian tube

Many women have what appear to be benign adnexal masses. Many times, removal of the masses with surgery is not necessary. Often surgery is performed unnecessarily, for fear that these masses could be cancer. There is not much information available for doctors to know how and when to follow these masses, or which ones will become cancer.

This study will combine information from centers all around the world regarding the behavior of all types of benign adnexal masses. The aim of this study is to develop decision tools for doctors to know the best way to treat these masses in order to improve the detection of ovarian cancer while at the same time reduce the number of unnecessary operations.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    15000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Multicentre Study to Examine the Short and Long Term Outcomes of the Conservative Management of Benign-looking Adnexal Masses and the Pre-operative Characterisation of Ovarian Tumours
    Study Start Date :
    Jan 1, 2012
    Anticipated Primary Completion Date :
    Dec 1, 2021
    Anticipated Study Completion Date :
    Dec 1, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    benign-looking adnexal masses

    Outcome Measures

    Primary Outcome Measures

    1. Frequency of complications such as rupture, torsion, or malignancy in patients with benign looking conservatively treated masses [Up to five years]

    Secondary Outcome Measures

    1. Test the published IOTA diagnostic models for predicting that a mass is malignant at first visit or benign [Up to five years]

      Also to predict complications (e.g. occurrence of malignancy and other) during long-term follow-up using the diagnostic models

    Other Outcome Measures

    1. Investigate factors related to the need for surgery during long-term follow-up [Up to five years]

    2. Study natural history of conservatively treated benign-looking adnexal masses [Up to five years]

      Also to establish descriptive curves of the longitudinal changes seen in parameters from conservatively managed benign tumors (for example, change in diameter, size of any solid component, number of papillations or color score)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Any woman at least 18 years old with an adnexal mass.

    • Any mass with benign ultrasound morphology may be suitable for conservative management.

    • Pregnant patients can be included, but their data will be analysed separately.

    Exclusion Criteria:
    • Cysts that are deemed to be clearly physiological and less than 3 cm in maximum diameter are not eligible for inclusion.

    • Any cyst with features of malignancy is excluded from the conservative management

    • The denial or withdrawal of oral informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 USF Health South Tampa Center for Advanced Healthcare Tampa Florida United States 33606

    Sponsors and Collaborators

    • KU Leuven

    Investigators

    • Principal Investigator: Dirk Timmerman, PhD, University Hospitals, KU Leuven

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Dirk Timmerman, Prof. Dr. Dirk Timmerman, KU Leuven
    ClinicalTrials.gov Identifier:
    NCT01698632
    Other Study ID Numbers:
    • IOTA5 S51375/B32220095331
    • USF IRB Pro00009001
    First Posted:
    Oct 3, 2012
    Last Update Posted:
    Apr 14, 2020
    Last Verified:
    Apr 1, 2020
    Keywords provided by Dirk Timmerman, Prof. Dr. Dirk Timmerman, KU Leuven
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 14, 2020